Novo Nordisk A/S (0QIU.IL)

875,10 +16,45 (+1,92%) Alla chiusura: 07:12PM BST

Novo Nordisk A/S

Novo Alle 1
Bagsvaerd 2880
Denmark
45 44 44 88 88
https://www.novonordisk.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 59.337

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Lars Fruergaard Jorgensen	Pres, CEO & Member of Management Board	32,3M	N/D	1966
Mr. Karsten Munk Knudsen	Exec. VP, CFO & Member of the Management Board	12,8M	N/D	1971
Mr. Henrik Ehlers Wulff	Exec. VP of Product Supply, Quality & IT and Member of the Management Board	12,9M	N/D	1970
Ms. Camilla Sylvest	Exec. VP of Commercial Strategy & Corp. Affairs and Member of the Management Board	12,6M	N/D	1972
Dr. Martin Holst Lange	Exec. VP of Devel. & Member of the Management Board	12,2M	N/D	1970
Dr. Marcus Schindler Ph.D.	EVP of Research & Early Devel., Chief Scientific Officer & Member of the Management Board	12,2M	N/D	1966
Mr. Maziar Mike Doustdar	Exec. VP of International Operations & Member of the Management Board	N/D	N/D	1970
Mr. Douglas J. Langa	Exec. VP of North America Operations & Member of Management Board	N/D	N/D	1966
Mr. Ludovic Helfgott	Exec. VP, Head of Rare Disease & Member of Management Board	N/D	N/D	1974
Ms. Tania Sabroe	Exec. VP of Global People & Organisation and Member of Management Board	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in DKK.

Descrizione

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Governance aziendale

L'ISS Governance QualityScore di Novo Nordisk A/S al 1 ottobre 2023 è 2. I criteri di valutazione fondamentali sono revisione: 2; Consiglio di Amministrazione: 3; diritti degli azionisti: 10; retribuzione: 1.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.